You are here

Award Data

For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Administrative Supplement to restore fee funds


    Project Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Optimizing Direct Delivery of Nucleic Acid Therapeutics

    SBC: FHC, INC.            Topic: NIMH

    Project Summary While nucleic acid therapeutics have shown promise in rodent and nonhuman primate models of CNS diseasesall double blind clinical trials to date have failedOne likely explanation for this failure is poor therapeutic distribution in targeted brain regionsFor examplepost mortem studies of patients with Parkinsonandapos s Disease receiving intraparenchymal injections of AAV NTN demons ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. A Novel Therapeutic that Harnesses MIcrotubules to Enhance Corneal Wound Healing Following an Alkaline Burn

    SBC: MicroCures Inc.            Topic: NEI

    The cornea is one of the most important tissues in the eye and its transparency is critical for good visual function in humansCorneal tissue injuries are the most common everyday issue for practicing ophthalmologists and can run the gamut in severityIn severe modelssuch as corneal alkaline burnsextensive healing is needed and often the burn victim is left with reduced visual acuityHealing of large ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. O-Glycan-dependent Immunotherapy for Cancer

    SBC: GlyTR Therapeutics, Inc.            Topic: 102

    Abstract For decadesthe treatment of cancer has relied on surgical resectionchemotherapy and or radiotherapyRecentlya number of immune based therapies have provided promising new approaches for cancer treatmentThe two most potent immunotherapies are monoclonal antibodymABbased bi specific proteinseg Bispecific T cell engagersBiTEand engineered Chimeric Antigen Receptor T cellsCAR TBoth act by indu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. The Microscopic Imaging of Epigenetic Landscape- NeuroDevelopment (MIEL-ND) assay: a high throughput platform to screen compounds for neurodevelopmental effects

    SBC: VALA SCIENCES, INC.            Topic: 101

    Neurodevelopmental diseasesNDDsAutism Spectrum DisorderASDIntellectual DisabilitiesBipolar disordersand Schizophreniaetcare prevalent and due to errors in neurodifferentiation and neurocircuitryWhile NDDsin many casesare due to inherited mutationsevidence is mounting that prenatal exposure to environmental toxicants also cause NDDs via disruption of epigeneticse gmodifications of histoneshistone t ...

    STTR Phase I 2018 Department of Health and Human Services
  6. In vitro and in vivo evaluation of elephant p53 (EP53) protein nanoparticles for pediatric osteosarcoma

    SBC: Peel Therapeutics, Inc            Topic: 102

    PROJECT SUMMARY ABSTRACT PEEL TherapeuticsIncis a life sciences company created to impact the lives of people with cancerBased on the research efforts of DrJoshua Schiffman and DrAvi SchroederPEEL TherapeuticsPEELhas created liposomal nanoparticles that have been loaded with elephant pEPproteins as a new class of anti cancer protein therapeuticsElephants have an unexpectedly low rate of cancer giv ...

    STTR Phase I 2018 Department of Health and Human Services
  7. Clinical Translation of a Caveolae Targeting Antibody for Enhancing Cancer Drug Delivery

    SBC: Cavatar LLC            Topic: NCI

    PROJECT SUMMARY This proposal aims to develop a novel caveolae targeting antibody for rapid clinical translationIts long term objective is to develop the caveolae pumping systeman active transendothelial transport pathwayto provide an effective solution to the delivery and toxicity problem of systemically administered chemotoxinsWork will be based on the current proprietary mouse monoclonal antibo ...

    STTR Phase I 2018 Department of Health and Human Services
  8. Optimization of Fatigue Test Signal Compression Using the Wavelet Transform

    SBC: ATA Engineering, Inc.            Topic: N18BT029

    Traditional approaches to accelerated fatigue testing rely on heuristic methods with thresholds based mostly on experience and engineering judgment. These methods generally do not apply to the multiaxial dynamic loading situations characteristic of most aerospace applications and often result in uncharacteristic fatigue damage and failure modes during testing. To overcome the limitations of tradit ...

    STTR Phase I 2018 Department of DefenseNavy
  9. Development of a Point of Care Diagnostic Screening test for Kawasaki disease

    SBC: L2 Diagnostics, LLC            Topic: NICHD

    ABSTRACT Kawasaki DiseaseKDis a febrile childhood vasculitis with potentially catastrophic clinical outcomesUntreatedone in five children develop coronary artery aneurysms causing significant morbidity and mortalityTypical KD presents as a febrile illness andgtdays in children andltyears oldThere are no diagnostic tests for KDit is diagnosed clinically based on a fever andgtdays with at leastofphy ...

    STTR Phase I 2018 Department of Health and Human Services
  10. Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity

    SBC: SignalRx Pharmaceuticals Inc.            Topic: 102

    Three CDKinhibitors were recently approved to treat breast cancerBrCAin combination regimentsDespite significant clinical activitytreatment of BrCA patients with these combinations does not result in a durable responseHencethere is an unmet medical need to develop targeted therapeutic agents which will augment the activity of CDKinhibitors in BrCA and other CDKcyclin D Myc dependent malignanciesA ...

    STTR Phase I 2018 Department of Health and Human Services
US Flag An Official Website of the United States Government